Ernexa Therapeutics Says ERNA-201 Showed Reduced Disease Severity vs. Untreated Controls In Preliminary Collagen-Induced Arthritis Mouse Study; Pauses ERNA-201 Preclinical Spending To Prioritize ERNA-101 IND Submission In Q4 2026

Loading news article.

Ernexa Therapeutics Says ERNA-201 Showed Reduced Disease Severity vs. Untreated Controls In Preliminary Collagen-Induced Arthritis Mouse Study; Pauses ERNA-201 Preclinical Spending To Prioritize ERNA-101 IND Submission In Q4 2026 | WAPE

Ernexa Therapeutics Says ERNA-201 Showed Reduced Disease Severity vs. Untreated Controls In Preliminary Collagen-Induced Arthritis Mouse Study; Pauses ERNA-201 Preclinical Spending To Prioritize ERNA-101 IND Submission In Q4 2026

Article summary

Related companies

Analyzed by WAPE AI.

Comments —